Corvus Pharmaceuticals, Inc. (CRVS)

NASDAQ: CRVS · IEX Real-Time Price · USD
0.870
-0.230 (-20.91%)
At close: Jun 24, 2022 4:00 PM
1.020
+0.150 (17.241%)
After-hours: Jun 24, 2022 7:59 PM EDT

Company Description

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies.

Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers.

The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer.

Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis.

Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines.

The company was incorporated in 2014 and is based in Burlingame, California.

Corvus Pharmaceuticals, Inc.
Country United States
Founded 2014
IPO Date Mar 23, 2016
Industry Biotechnology
Sector Health Care
Employees 28
CEO Richard Miller

Contact Details

Address:
863 Mitten Rd Ste 102
Burlingame, California 94010-1311
United States
Phone 650 900 4520
Website corvuspharma.com

Stock Details

Ticker Symbol CRVS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001626971

Key Executives

Name Position
Dr. Richard A. Miller M.D. Co-Founder, President, Chief Executive Officer and Chairman
Dr. Peter A. Thompson FACP, M.D. Co-Founder and Independent Director
Leiv Lea Chief Financial Officer
Dr. William Benton Jones Ph.D. Senior Vice President of Pharmaceutical Development
Dr. Erik J. Verner Ph.D. Co-Founder
Alan C. Mendelson Esq. Secretary

Latest SEC Filings

Date Type Title
Jun 17, 2022 4 Statement of changes in beneficial ownership of securities
Jun 17, 2022 4 Statement of changes in beneficial ownership of securities
Jun 17, 2022 4 Statement of changes in beneficial ownership of securities
Jun 17, 2022 4 Statement of changes in beneficial ownership of securities
Jun 17, 2022 4 Statement of changes in beneficial ownership of securities
Jun 17, 2022 4 Statement of changes in beneficial ownership of securities
Jun 17, 2022 8-K Current report
Jun 6, 2022 4 Statement of changes in beneficial ownership of securities
May 5, 2022 S-8 Securities to be offered to employees in employee benefit plans
May 5, 2022 10-Q Quarterly report [Sections 13 or 15(d)]